Figures are the mean ± SD unless otherwise stated. In some cases, results are given as a range. F: oral bioavailability which is 49% ; amean, standard deviation is not available; bmedian; GA: gestational age; PNA: postnatal age; BW: body weight; : β-phase elimination; Cl: clearance; Vd: apparent volume of distribution; na: not available; IV: intravenously; PO: by mouth; Note A: neonates were suffering from congenital heart disease (), upper airway infection (), pneumonia (), postcardiac surgery (), pulmonary hypertension (), and other (); Note B: midazolam was administered via a central or peripheral venous catheter; Note C: midazolam was administered intravenously as a continuous infusion to 109 infants, as a bolus dose to 22 infants, and as a combination of both to 56 infants. The bolus dose was 210 ± 239 µg/kg. The continuous infusion was 69 ± 63 µg/kg per h; Note D: all neonates received midazolam during artificial ventilation; Note E: neonates undergoing mechanical ventilation had a body weight <1,500 g.